Cargando…

The prevalence of alpha-1 antitrypsin deficiency in Ireland

BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical evidence is the Z mutation, while the S mutation is associated with a milder plasma d...

Descripción completa

Detalles Bibliográficos
Autores principales: Carroll, Tomás P, O'Connor, Catherine A, Floyd, Olwen, McPartlin, Joseph, Kelleher, Dermot P, O'Brien, Geraldine, Dimitrov, Borislav D, Morris, Valerie B, Taggart, Clifford C, McElvaney, Noel G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155497/
https://www.ncbi.nlm.nih.gov/pubmed/21752289
http://dx.doi.org/10.1186/1465-9921-12-91
_version_ 1782210125767901184
author Carroll, Tomás P
O'Connor, Catherine A
Floyd, Olwen
McPartlin, Joseph
Kelleher, Dermot P
O'Brien, Geraldine
Dimitrov, Borislav D
Morris, Valerie B
Taggart, Clifford C
McElvaney, Noel G
author_facet Carroll, Tomás P
O'Connor, Catherine A
Floyd, Olwen
McPartlin, Joseph
Kelleher, Dermot P
O'Brien, Geraldine
Dimitrov, Borislav D
Morris, Valerie B
Taggart, Clifford C
McElvaney, Noel G
author_sort Carroll, Tomás P
collection PubMed
description BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical evidence is the Z mutation, while the S mutation is associated with a milder plasma deficiency. AATD is an under-diagnosed condition and the World Health Organisation recommends targeted detection programmes for AATD in patients with chronic obstructive pulmonary disease (COPD), non-responsive asthma, cryptogenic liver disease and first degree relatives of known AATD patients. METHODS: We present data from the first 3,000 individuals screened following ATS/ERS guidelines as part of the Irish National Targeted Detection Programme (INTDP). We also investigated a DNA collection of 1,100 individuals randomly sampled from the general population. Serum and DNA was collected from both groups and mutations in the SERPINA1 gene detected by phenotyping or genotyping. RESULTS: The Irish National Targeted Detection Programme identified 42 ZZ, 44 SZ, 14 SS, 430 MZ, 263 MS, 20 IX and 2 rare mutations. Analysis of 1,100 randomly selected individuals identified 113 MS, 46 MZ, 2 SS and 2 SZ genotypes. CONCLUSION: Our findings demonstrate that AATD in Ireland is more prevalent than previously estimated with Z and S allele frequencies among the highest in the world. Furthermore, our targeted detection programme enriched the population of those carrying the Z but not the S allele, suggesting the Z allele is more important in the pathogenesis of those conditions targeted by the detection programme.
format Online
Article
Text
id pubmed-3155497
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31554972011-08-13 The prevalence of alpha-1 antitrypsin deficiency in Ireland Carroll, Tomás P O'Connor, Catherine A Floyd, Olwen McPartlin, Joseph Kelleher, Dermot P O'Brien, Geraldine Dimitrov, Borislav D Morris, Valerie B Taggart, Clifford C McElvaney, Noel G Respir Res Research BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) results from mutations in the SERPINA1 gene and classically presents with early-onset emphysema and liver disease. The most common mutation presenting with clinical evidence is the Z mutation, while the S mutation is associated with a milder plasma deficiency. AATD is an under-diagnosed condition and the World Health Organisation recommends targeted detection programmes for AATD in patients with chronic obstructive pulmonary disease (COPD), non-responsive asthma, cryptogenic liver disease and first degree relatives of known AATD patients. METHODS: We present data from the first 3,000 individuals screened following ATS/ERS guidelines as part of the Irish National Targeted Detection Programme (INTDP). We also investigated a DNA collection of 1,100 individuals randomly sampled from the general population. Serum and DNA was collected from both groups and mutations in the SERPINA1 gene detected by phenotyping or genotyping. RESULTS: The Irish National Targeted Detection Programme identified 42 ZZ, 44 SZ, 14 SS, 430 MZ, 263 MS, 20 IX and 2 rare mutations. Analysis of 1,100 randomly selected individuals identified 113 MS, 46 MZ, 2 SS and 2 SZ genotypes. CONCLUSION: Our findings demonstrate that AATD in Ireland is more prevalent than previously estimated with Z and S allele frequencies among the highest in the world. Furthermore, our targeted detection programme enriched the population of those carrying the Z but not the S allele, suggesting the Z allele is more important in the pathogenesis of those conditions targeted by the detection programme. BioMed Central 2011 2011-07-13 /pmc/articles/PMC3155497/ /pubmed/21752289 http://dx.doi.org/10.1186/1465-9921-12-91 Text en Copyright ©2011 Carroll et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Carroll, Tomás P
O'Connor, Catherine A
Floyd, Olwen
McPartlin, Joseph
Kelleher, Dermot P
O'Brien, Geraldine
Dimitrov, Borislav D
Morris, Valerie B
Taggart, Clifford C
McElvaney, Noel G
The prevalence of alpha-1 antitrypsin deficiency in Ireland
title The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_full The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_fullStr The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_full_unstemmed The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_short The prevalence of alpha-1 antitrypsin deficiency in Ireland
title_sort prevalence of alpha-1 antitrypsin deficiency in ireland
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155497/
https://www.ncbi.nlm.nih.gov/pubmed/21752289
http://dx.doi.org/10.1186/1465-9921-12-91
work_keys_str_mv AT carrolltomasp theprevalenceofalpha1antitrypsindeficiencyinireland
AT oconnorcatherinea theprevalenceofalpha1antitrypsindeficiencyinireland
AT floydolwen theprevalenceofalpha1antitrypsindeficiencyinireland
AT mcpartlinjoseph theprevalenceofalpha1antitrypsindeficiencyinireland
AT kelleherdermotp theprevalenceofalpha1antitrypsindeficiencyinireland
AT obriengeraldine theprevalenceofalpha1antitrypsindeficiencyinireland
AT dimitrovborislavd theprevalenceofalpha1antitrypsindeficiencyinireland
AT morrisvalerieb theprevalenceofalpha1antitrypsindeficiencyinireland
AT taggartcliffordc theprevalenceofalpha1antitrypsindeficiencyinireland
AT mcelvaneynoelg theprevalenceofalpha1antitrypsindeficiencyinireland
AT carrolltomasp prevalenceofalpha1antitrypsindeficiencyinireland
AT oconnorcatherinea prevalenceofalpha1antitrypsindeficiencyinireland
AT floydolwen prevalenceofalpha1antitrypsindeficiencyinireland
AT mcpartlinjoseph prevalenceofalpha1antitrypsindeficiencyinireland
AT kelleherdermotp prevalenceofalpha1antitrypsindeficiencyinireland
AT obriengeraldine prevalenceofalpha1antitrypsindeficiencyinireland
AT dimitrovborislavd prevalenceofalpha1antitrypsindeficiencyinireland
AT morrisvalerieb prevalenceofalpha1antitrypsindeficiencyinireland
AT taggartcliffordc prevalenceofalpha1antitrypsindeficiencyinireland
AT mcelvaneynoelg prevalenceofalpha1antitrypsindeficiencyinireland